Newsflash: Senate Finance Committee starts investigation of Merck, Schering-Plough, AHA and ACC.

Newsflash--more to come: Senator Chuck Grassley, Ranking Member of the Committee on Finance, is asking drug makers Schering-Plough and Merck to explain when the companies first unblinded ENHANCE trial results and to account for sales and payments made for the cholesterol drug Vytorin to Medicaid. Senator Grassley has also written to the Securities and Exchange Commission, the
American Heart Association and the American College of Cardiology regarding this matter.

Sen. Grassley asks questions about controversy over delayed release of drug study involving Vytorin

(*) Grassley letter to the American Heart Association

(*) Grassley letter to the American College of Cardiology

(*) Grassley letter to Schering-Plough

(*) Grassley letter to Merck

(*) Grassley letter to the Securities and Exchange Commission